Você procurou por: limfoproliferativnimi (Esloveno - Inglês)

poročali so o z ebv povezanimi limfoproliferativnimi boleznimi.
ebv-associated lymphoproliferative disorder has been reported.

poročali so o z ebv povezanimi limfoproliferativnimi boleznimi, ki so bile v nekaterih primerih smrtne.
ebv-associated lymphoproliferative disorders, in some cases fatal, have been reported.

Če hemoglobin pri bolnikih s čvrstimi tumorji ali limfoproliferativnimi malignomi preseže 120 g/ l (7, 5 ve
in patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/ dl (7.5 mmol/ l), the dosage adaptation described in section 4.2 should be closely respected, in m

v povezavi z zdravljenjem s takrolimusom so poročali o benignih in malignih neoplazmah, vključno z limfoproliferativnimi boleznimi, povezanimi z ebv in kožnimi malignomi.
benign as well as malignant neoplasms including ebv-associated lymphoproliferative disorders and skin malignancies have been reported in association with tacrolimus treatment.

v prospektivni, randomizirani, dvojno slepi s placebom kontrolirani študiji pri 344 anemičnih bolnikih z limfoproliferativnimi malignomi, ki so dobivali kemoterapijo, so ugotovili značilno zmanjšanje
er every three weeks being comparable to once weekly administration with respect to the incidence of subjects receiving at least one red blood cell transfusion from week 5 to the end of treatment phase. ng in a prospective, randomised double-blind, placebo-controlled study conducted in 344 anaemic lo patients with lymphoproliferative malignancies receiving chemotherapy there was a significant reduction in transfusion requirements and an improvement in haemoglobin response (p < 0.001). no

Če hemoglobin pri bolnikih s čvrstimi tumorji ali limfoproliferativnimi malignomi preseže 120 g/l (7,5 mmol/l)), natančno upoštevajte prilagoditev odmerka, opisano v poglavju 4.2, da boste zmanjšali morebitno tveganje za trombembolične incidente.
in patients with solid tumours or lymphoproliferative malignancies, if the haemoglobin value exceeds 12 g/dl (7.5 mmol/l), the dosage adaptation described in section 4.2 should be closely respected, in order to minimise the potential risk of thromboembolic events.